Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognosis of small-cell lung cancer since the introduction of amrubicin.
Suzuki H, Hirashima T, Kobayashi M, Sasada S, Okamoto N, Tamiya M, Matsuura Y, Morishita N, Uehara N, Matsui K, Kawase I. Suzuki H, et al. Among authors: hirashima t. Med Oncol. 2011 Dec;28(4):1430-5. doi: 10.1007/s12032-010-9623-z. Epub 2010 Jul 15. Med Oncol. 2011. PMID: 20632217
Long-term amrubicin chemotherapy for small-cell lung cancer.
Higashiguchi M, Suzuki H, Hirashima T, Kobayashi M, Goya S, Okamoto N, Matsuura Y, Tamiya M, Morishita N, Kawase I. Higashiguchi M, et al. Among authors: hirashima t. Anticancer Res. 2012 Apr;32(4):1423-7. Anticancer Res. 2012. PMID: 22493380
Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for non-small cell lung cancer after failure of platinum-doublet chemotherapy.
Tamiya M, Tamiya A, Nakao K, Asami K, Okishio K, Satomu M, Shiroyama T, Morishita N, Suzuki H, Sasada S, Okamoto N, Okishio K, Kawaguchi T, Kobayashi M, Atagi S, Hirashima T, Kawase I. Tamiya M, et al. Among authors: hirashima t. Anticancer Res. 2012 Aug;32(8):3553-7. Anticancer Res. 2012. PMID: 22843945
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M, Tamiya A, Yasue T, Nakao K, Omachi N, Shiroyama T, Tani E, Hamaguchi M, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Hirashima T. Tamiya M, et al. Among authors: hirashima t. Anticancer Res. 2016 Jun;36(6):2939-44. Anticancer Res. 2016. PMID: 27272808
Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, Tsuji T, Takeuchi N, Isa SI, Omachi N, Okamoto N, Suzuki H, Okishio K, Iwazaki A, Imai K, Hirashima T, Atagi S. Tamiya A, et al. Among authors: hirashima t. Anticancer Res. 2017 Aug;37(8):4177-4182. doi: 10.21873/anticanres.11806. Anticancer Res. 2017. PMID: 28739703 Clinical Trial.
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
Tamiya A, Tamiya M, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Inoue T, Okishio K, Nishino K, Kumagai T, Suzuki H, Hirashima T, Imamura F, Atagi S. Tamiya A, et al. Among authors: hirashima t. Anticancer Res. 2017 Sep;37(9):5199-5205. doi: 10.21873/anticanres.11943. Anticancer Res. 2017. PMID: 28870955
392 results